Results 1 to 10 of about 4,483 (147)
Medication-Related Osteonecrosis: Why the Jawbone?
Dentistry Journal, 2023 Medication-related osteonecrosis of the jaw (MRONJ) has emerged as a complication of anti-resorptive medications. Despite its low incidence rate, this problem has gained attention in recent years due to its devastating consequences and lack of preventive
Mohammed E Elsalanty, Sydney Kuehn
exaly +3 more sources
Japanese Dental Science Review, 2019 Summary: Since Marx reported on osteonecrosis of the jaw caused by the injectable bisphosphonates (BPs) pamidronate and zoledronate, there have been numerous reports not only in Western countries, but in Japan as well, of bisphosphonate-related ...
Takahiko Shibahara
exaly +3 more sources
Brazilian Journal of Otorhinolaryngology, 2022 Introduction: Increased incidence of localized osteonecrosis in the jaw bones caused by bisphosphanate use and reduced quality of life of the patients led researchers to diagnose the disease in the early period and to investigate the effective treatment ...
Onur Şahin +5 more
doaj +1 more source
Applied Sciences, 2022 Osteonecrosis of the jaw represents interference by external and internal factors in the natural bone remodeling system. Numerous bone remodeling agents (BMAs), such as bisphosphonates, denosumab, and tyrosine kinase inhibitors, can lead to medication ...
Mihai Vlad Golu +6 more
doaj +1 more source
BMC Oral Health, 2021 Background Accurate documentation of a patient’s prior medication use and awareness of side effects associated with anti-osteoporotic agents can assist dentists to prevent medication-related osteonecrosis of the jaw. I aimed to determine the awareness of
A. Lum Han
doaj +1 more source
Dentistry Journal, 2021 Medication-related osteonecrosis of the jaw (MRONJ) frequently affects patients after treatments with bisphosphonates or denosumab, especially with high doses in patients with bone osteoporosis, neoplastic metastases, or possibly anti-angiogenic ...
Antonio Cortese +3 more
doaj +1 more source
Clinical Case Reports, 2023 Key Clinical Message Chronic use of bisphosphonates, in combination with immunosuppressive therapy, increases the risk of jaw osteonecrosis. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a ...
Kazuhiko Iwasaki, Akihito Okazaki
doaj +1 more source
Fatal infectious encephalitis as a complication of medication-related osteonecrosis of the jaw
Oral and Maxillofacial Surgery Cases, 2020 We present a unique case of bacterial encephalitis in a 79-year-old female due to progression of medication-related osteonecrosis of the jaw. The occurrence of this life-threatening neurologic condition following the expansion of medication-related ...
Hye-Won Kim +3 more
doaj +1 more source
Romosozumab-associated medication-related osteonecrosis of the jaw
Oral and Maxillofacial Surgery Cases, 2023 This is the first reported case of medication-related osteonecrosis of the jaw (MRONJ) resulting from the use of romosozumab, a new anti-resorptive medication that functions through inhibition of sclerostin.
Benjamin Palla +4 more
doaj +1 more source
The Use of Photodynamic Therapy on Medication-Related Osteonecrosis of the Jaws: Animal Study
Balkan Journal of Dental Medicine, 2021 Background/Aim: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) was first introduced in 2003 and its scope was expanded by the name medication-related osteonecrosis of the jaw (MRONJ), since 2014.
Karapinar Gökay +3 more
doaj +1 more source